Condensed Consolidated Statements Of Cash Flows (USD $) In Thousands	9 Months Ended
	Sep. 30, 2011	Sep. 30, 2010
Operating activities:
Net loss	$ (38,320)	$ (19,199)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	1,142	572
Loss on disposal of property and equipment	6
Accretion (amortization) of premium/discount on marketable securities	1,025	331
Amortization of debt discount	66	60
Amortization of loan fees	8
Noncash interest expense (income) - net	(4)	(34)
Issuance of common stock in connection with professional services rendered	16
Issuance of common stock warrant in connection with professional services		6
Stock-based compensation expense	7,575	955
Revaluation of preferred stock warrant liability	3,637	638
Changes in operating assets and liabilities:
Accounts receivable	(486)	1,890
Unbilled revenue	(1,697)
Inventories	(3,194)
Prepaid expenses and other current assets	(2,566)	(237)
Other assets	69	(4)
Accounts payable	(956)	1,397
Accrued liabilities	3,093	142
Deferred revenue	(449)	(1,967)
Other current and long-term liabilities	(26)	484
Net cash used in operating activities	(31,061)	(14,966)
Investing activities:
Purchases of property, plant and equipment	(13,241)	(1,717)
Proceeds received from sale of equipment	290
Purchases of marketable securities	(137,992)	(31,278)
Proceeds from sales of marketable securities	3,118
Maturities of marketable securities	45,707	15,000
Restricted cash	(50)	(269)
Net cash used in investing activities	(102,168)	(18,264)
Financing activities:
Repayments under loan agreements	(34)	(1,858)
Proceeds from the issuance of convertible preferred stock		60,000
Payment for equity financing costs		(232)
Proceeds from the issuance of common stock, net of repurchases	409	103
Early exercise of stock options subject to repurchase	(61)	316
Payments received on promissory notes to stockholders	1,601
Proceeds from borrowings under loan agreements	15,000
Payment for loan costs/fees	(90)
Proceeds from exercise of common and preferred stock warrants	37
Proceeds from issuance of common stock in initial public offering, net of underwriting discounts and commission	201,236
Offering costs	(3,852)
Net cash provided by financing activities	214,246	58,329
Effect of exchange rates on cash and cash equivalents	(314)
Net increase in cash and cash equivalents	80,703	25,099
Cash and cash equivalents - Beginning of period	32,497	19,845
Cash and cash equivalents - End of period	113,200	44,944
Supplemental disclosures of cash flow information:
Interest paid in cash	254	162
Income taxes paid in cash
Supplemental disclosure of noncash investing and financing activities:
Accretion of redeemable convertible preferred stock	60	103
Capital assets in accounts payable and accrued liabilities	1,002	123
Accrued offering costs	356
Addition of land, building and equipment under notes payable	5,248	265
Change in unrealized gain (loss) on investments	343
Conversion of convertible preferred stock to common stock upon initial public offering	128,374
Reclassification of preferred stock warrant liability	6,598
Reclassification of deferred offering costs to additional paid-in capital upon initial public offering	$ 4,180